Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 73

Sort by

Sort Order Select

Journal Articles

Healthcare Resource Utilization and Costs of Medicare Fee for Service Beneficiaries Newly Diagnosed with Moderate to Severe Non-Advanced Systemic Mastocytosis

Erin M. Sullivan, Jenna Cohen, Chelsea Norregaard, Uyen Nguyen, Chris Sloan, Allison Petrilla, Alison Silverstein, Anne Murunga, Jill Schinkel

Blood (2021) 138 (Supplement 1): 4049.

https://doi.org/10.1182/blood-2021-150686

Published: 2021

Journal Articles

Healthcare Resource Utilization and Costs of Advanced Systemic Mastocytosis Among Medicare Fee for Service Beneficiaries

Erin M. Sullivan, Jenna Cohen, Chelsea Norregaard, Uyen Nguyen, Chris Sloan, Allison Petrilla, Alison Silverstein, Anne Murunga, Jill Schinkel

Blood (2021) 138 (Supplement 1): 4048.

https://doi.org/10.1182/blood-2021-147515

Published: 2021

Journal Articles

Access to CAR-T Cell Therapy in Underrepresented Populations: A Multicenter Cohort Study of Pediatric and Young Adult ALL Patients

Anurekha G. Hall, Lena E. Winestone, Erin M. Sullivan, Qian Vicky Wu, Adam J. Lamble, Mark C. Walters, Paibel Aguayo-Hiraldo, Lourdes Baez Conde, Tumaini R. Coker, Hema Dave, Dana Dornsife, Amy K. Keating, Diana M. Merino, Bonnie Ramsey, Julie R. Park, Anurag K. Agrawal

Blood (2021) 138 (Supplement 1): 339.

https://doi.org/10.1182/blood-2021-148256

Published: 2021

Journal Articles

Patient Reported Outcomes Among Systemic Mastocytosis (SM) Patients in Routine Clinical Practice: Results from the TouchStone Survey

Ruben A. Mesa, MD FACP, Erin M. Sullivan, PhD, David Dubinsky, MBA, BS, Brittany Carroll, MBA, Valerie M. Slee, RN, BSN, Susan Jennings, PhD, Celeste Finnerty, PhD, Linda Bohannon, RN, BSN, MSM, Susan Mathias, MPH, Mariana Castells, MD PhD

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-137480

Published: 2020

Journal Articles

Perceptions of Patient Disease Burden and Management Approaches of Systemic Mastocytosis (SM) By Healthcare Providers: Results from the TouchStone SM Survey

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-137544

Published: 2020

Journal Articles

The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Taiga Nishihori, MD, Melissa Alsina, MD, Jose Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Rachid Baz, MD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Jongphil Kim, PhD, Michael Dumala, Joel G. Turner, PhD, Daniel M Sullivan, MD

Blood (2019) 134 (Supplement_1): 3314.

https://doi.org/10.1182/blood-2019-131321

Published: 2019

Journal Articles

How I treat refractory chronic graft-versus-host disease

Stefanie Sarantopoulos, Adela R. Cardones, Keith M. Sullivan

Blood (2019) 133 (11): 1191–1200.

https://doi.org/10.1182/blood-2018-04-785899

Published: 2019

Includes: Supplemental data

Journal Articles

Deep and Durable Responses with Selinexor, Daratumumab, and Dexamethasome (SDd) in Patients with Multiple Myeloma (MM) Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs: Results of Phase 1b Study of SDd

Blood (2018) 132 (Supplement 1): 599.

https://doi.org/10.1182/blood-2018-99-117201

Published: 2018

Journal Articles

Hematopoietic Stem Cell Transplantation at Home

Anthony D. Sung, MD, Krista R. Nichols, RN, MSN, AOCNS, Julia A. Messina, MD, Kristi Romero, BA, Tara Dalton, MBS, Amy Bush, BA, Megan Covington, BS, Rebecca Shelby, PhD, Jennifer Frith, RN, MSN, OCN, Cristina J. Gasparetto, MD, Mitchell E. Horwitz, MD, Gwynn D. Long, MD, Richard Lopez, MD, David A. Rizzieri, MD, Stefanie Sarantopoulos, MD PhD, Keith M. Sullivan, MD, Nelson J. Chao, MDM.B.A

Blood (2017) 130 (Supplement 1): 745.

https://doi.org/10.1182/blood.V130.Suppl_1.745.745

Published: 2017

Journal Articles

Phase I/II Study of Liposomal Doxorubicin (DOX) in Combination with Selinexor (SEL) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma (RRMM)

Rachid Baz, MD, Jeffrey A Zonder, MD, Kenneth H Shain, MD PhD, Melissa Alsina, MD, Jason B. Brayer, PhDMD, Mark Melody, Joel G. Turner, PhD, Jana L Dawson, Jongphil Kim, Daniel M Sullivan, MD

Blood (2017) 130 (Supplement 1): 3095.

https://doi.org/10.1182/blood.V130.Suppl_1.3095.3095

Published: 2017

Journal Articles

Spk-9001: Adeno-Associated Virus Mediated Gene Transfer for Hemophilia B Achieves Sustained Mean Factor IX Activity Levels of >30% without Immunosuppression

Blood (2016) 128 (22): 3.

https://doi.org/10.1182/blood.V128.22.3.3

Published: 2016

Journal Articles

The Synergistic Effect of Melphalan and XPO1 Inhibition in Pre-Clinical Models of Multiple Myeloma

Yan Cui, MD, Joel G Turner, PhD, Jana L Dawson, BS, Juan A Gomez, BS, Kenneth H. Shain, MD PhD, Mark B Meads, PhD, Erkan Baloglu, PhD, William S. Dalton, PhD MD, Taiga Nishihori, MD, Daniel M Sullivan, MD

Blood (2016) 128 (22): 5662.

https://doi.org/10.1182/blood.V128.22.5662.5662

Published: 2016

Journal Articles

Combination Therapy with Bortezomib or Carfilzomib and Selinexor Induces Nuclear Localization of Ikbα and Overcomes Acquired Proteasome Inhibitor Resistance in Human Multiple Myeloma

Joel G Turner, PhD, Trinayan Kashyap, MS, Jana L Dawson, BS, Juan A Gomez, BS, Alexis Bauer, BS, Steven Grant, MD, Yun Dai, PhD, Kenneth H. Shain, MD PhD, Mark B Meads, PhD, Yosef Landesman, PhD, Daniel M Sullivan, MD

Blood (2016) 128 (22): 3299.

https://doi.org/10.1182/blood.V128.22.3299.3299

Published: 2016

Journal Articles

Adult Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation, Fludarabine, and Thiotepa Conditioning

Sarah Anand, MD, Samantha Thomas, Kelly Corbet, Cristina Gasparetto, MD, Richard Lopez, MD, Gwynn D. Long, MD, Ashley K. Morris, PharmD, David A. Rizzieri, MD, Stefanie Sarantopoulos, MD PhD, Keith M Sullivan, MD, Anthony D. Sung, MD, Nelson J. Chao, MD, Mitchell E. Horwitz, MD

Blood (2016) 128 (22): 3395.

https://doi.org/10.1182/blood.V128.22.3395.3395

Published: 2016

Journal Articles

Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma

Rachid C. Baz, Thomas G. Martin, III, Hui-Yi Lin, Xiuhua Zhao, Kenneth H. Shain, Hearn J. Cho, Jeffrey L. Wolf, Anuj Mahindra, Ajai Chari, Daniel M. Sullivan, Lisa A. Nardelli, Kenneth Lau, Melissa Alsina, Sundar Jagannath

Blood (2016) 127 (21): 2561–2568.

https://doi.org/10.1182/blood-2015-11-682518

Published: 2016

Includes: Supplemental data

Journal Articles

Results of a Multicenter Pilot Investigation of Bone Marrow Transplantation in Adults with Sickle Cell Disease (STRIDE)

Lakshmanan Krishnamurti, MD, Keith M. Sullivan, MD, Naynesh R. Kamani, MD, Edmund K Waller, MD PhD, Allistair Abraham, MD, Federico Campigotto, MS, Wandi Zhang, MD, Shannon Smith, MSN, Kathryn L. Hassell, MD, Laura Decastro, MD, Catherine J Wu, MD, Donna S. Neuberg, Sc.D., Mark C. Walters, MD

Blood (2015) 126 (23): 543.

https://doi.org/10.1182/blood.V126.23.543.543

Published: 2015

Journal Articles

Combination Therapy of Selinexor with Bortezomib or Carfilzomib Overcomes Drug Resistance to Proteasome Inhibitors (PI) in Human Multiple Myeloma

Daniel M Sullivan, MD, Trinayan Kashyap, MS, Jana L Dawson, BS, Yosef Landesman, PhD, Steven Grant, MD, Kenneth H. Shain, MD PhD, Yun Dai, PhD, Michael Kauffman, MD PhD, Sharon Shacham, Joel G Turner, PhD

Blood (2015) 126 (23): 3048.

https://doi.org/10.1182/blood.V126.23.3048.3048

Published: 2015

Journal Articles

Next Generation XPO1 Inhibitor KPT-8602 for the Treatment of Drug-Resistant Multiple Myeloma

Joel G Turner, PhD, Jana L Dawson, BS, Christopher L Cubitt, PhD, Erkan Baluglo, PhD, Steven Grant, MD, Yun Dai, PhD, Kenneth H Shain, MD PhD, William S. Dalton, PhD MD, Sharon Shacham, William Senapedis, PhD, Daniel M Sullivan, MD

Blood (2015) 126 (23): 1818.

https://doi.org/10.1182/blood.V126.23.1818.1818

Published: 2015

Journal Articles

Melphalan and XPO1 Inhibitor Combination Therapy for the Treatment of Multiple Myeloma

Joel G Turner, PhD, Jana L Dawson, BS, Steven Grant, MD, Kenneth H. Shain, MD PhD, Yun Dai, MD PhD, Chris Cubitt, PhD, Rachid Baz, MD, Taiga Nishihori, MD, Michael Kauffman, MD PhD, Sharon Shacham, PhD MBA, Daniel M Sullivan, MD

Blood (2014) 124 (21): 2084.

https://doi.org/10.1182/blood.V124.21.2084.2084

Published: 2014

Journal Articles

Subsequent Primary Malignancies Among Multiple Myeloma Patients Treated with or without Lenalidomide

Dana E Rollison, PhD, Rami Komrokji, MD, Ji-Hyun Lee, PhD, Shalaka S Hampras, PhD, William Fulp, Kate Fisher, MA, Rachid Baz, MD, Taiga Nishihori, MD, Marta Olesnyckyj, Laurie Kenvin, BSN, RN, Robert D. Knight, MD, Daniel M Sullivan, MD, Melissa Alsina, MD, William Dalton, PhD MD, Kenneth H. Shain, MD PhD

Blood (2014) 124 (21): 2129.

https://doi.org/10.1182/blood.V124.21.2129.2129

Published: 2014

NARROW

Healthcare Resource Utilization and Costs of Medicare Fee for Service Beneficiaries Newly Diagnosed with Moderate to Severe Non-Advanced Systemic Mastocytosis

Healthcare Resource Utilization and Costs of Advanced Systemic Mastocytosis Among Medicare Fee for Service Beneficiaries

Access to CAR-T Cell Therapy in Underrepresented Populations: A Multicenter Cohort Study of Pediatric and Young Adult ALL Patients

Patient Reported Outcomes Among Systemic Mastocytosis (SM) Patients in Routine Clinical Practice: Results from the TouchStone Survey

Perceptions of Patient Disease Burden and Management Approaches of Systemic Mastocytosis (SM) By Healthcare Providers: Results from the TouchStone SM Survey

The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

How I treat refractory chronic graft-versus-host disease

Deep and Durable Responses with Selinexor, Daratumumab, and Dexamethasome (SDd) in Patients with Multiple Myeloma (MM) Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs: Results of Phase 1b Study of SDd

Hematopoietic Stem Cell Transplantation at Home

Phase I/II Study of Liposomal Doxorubicin (DOX) in Combination with Selinexor (SEL) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma (RRMM)

Spk-9001: Adeno-Associated Virus Mediated Gene Transfer for Hemophilia B Achieves Sustained Mean Factor IX Activity Levels of >30% without Immunosuppression

The Synergistic Effect of Melphalan and XPO1 Inhibition in Pre-Clinical Models of Multiple Myeloma

Combination Therapy with Bortezomib or Carfilzomib and Selinexor Induces Nuclear Localization of Ikbα and Overcomes Acquired Proteasome Inhibitor Resistance in Human Multiple Myeloma

Adult Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation, Fludarabine, and Thiotepa Conditioning

Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma

Results of a Multicenter Pilot Investigation of Bone Marrow Transplantation in Adults with Sickle Cell Disease (STRIDE)

Combination Therapy of Selinexor with Bortezomib or Carfilzomib Overcomes Drug Resistance to Proteasome Inhibitors (PI) in Human Multiple Myeloma

Next Generation XPO1 Inhibitor KPT-8602 for the Treatment of Drug-Resistant Multiple Myeloma

Melphalan and XPO1 Inhibitor Combination Therapy for the Treatment of Multiple Myeloma

Subsequent Primary Malignancies Among Multiple Myeloma Patients Treated with or without Lenalidomide

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only